Innocan Pharma's LPT-CBD Proves Effective in Pain Relief for Dogs, Surpassing Placebo

Innocan Pharma's Breakthrough in Pain Relief for Dogs

In a significant advancement for veterinary medicine, Innocan Pharma Corporation has announced promising results from a clinical study investigating the efficacy of its LPT-CBD product in alleviating pain in dogs suffering from osteoarthritis. The study, published in the reputable journal Frontiers in Veterinary Science, provides compelling evidence that LPT-CBD not only reduces pain effectively but does so more successfully than a placebo.

Study Overview

The randomized, blinded, placebo-controlled crossover clinical trial focused on eight client-owned dogs diagnosed with naturally occurring osteoarthritis. These dogs were administered two different treatments: 7 mg/kg of LPT-CBD and an identical amount of placebo, spaced four weeks apart. The pet owners, alongside veterinary specialists, monitored the dogs, assessing improvements in behavior and functionality, and documenting pain levels.

Key Findings

1. Behavioral Improvements: An overwhelming 100% of dog owners reported improved function in their pets following LPT-CBD treatment, compared to just 25% improvement noted after administering placebo (p = 0.0217).

2. Pain Reduction: The study also observed a significant decrease in lameness and pain following LPT-CBD treatment, with notable scoring reductions using visual scales for both (p = 0.033 for lameness and p = 0.005 for pain).

3. Sustained Release: LPT-CBD demonstrated a sustained-release profile, maintaining measurable plasma CBD concentrations for up to four weeks post-injection, suggesting prolonged therapeutic effects.

4. Tolerability: Notably, all participating dogs tolerated the LPT-CBD well, with only minor temporary issues such as a brief fever and mild injection-site swelling, both of which resolved independently within a couple of days.

According to Dr. Eyal Kalo, Innocan's Vice President of Research and Development, the results are encouraging not just for veterinary applications, but potentially for human medical therapies as well. Dr. Kalo indicated ongoing discussions with the FDA pertaining to advancing LPT-CBD's approval for both veterinary and human use.

Expert Commentary

Professor Chezy Barenholz, who heads Innocan’s Advisory Board, emphasized the importance of these findings, stating that LPT-CBD's harm-reduction capabilities, compared to placebo treatments, could transform pain management strategies for both pets and their owners. The cumulative effects of the study bolster previous findings that highlighted LPT-CBD's potential benefits across various animal species, including dogs and goats.

Conclusion and Future Directions

As Innocan positions itself as a leader in pharmaceutical innovation, this study marks a pivotal moment in veterinary medicine—combining scientific advancement with practical animal care. Following their successful findings, Innocan is focused on expanding the reach of LPT-CBD, targeting a broader market for pain management. The company continues to explore regulatory pathways to ensure LPT-CBD's availability both for veterinarians and potential human applications in pain management.

Given this promising evidence, pet owners suffering from the struggles of managing their canine companions' pain can look forward to advancements in treatment options that promise lasting comfort and improved quality of life.

For additional information about Innocan Pharma and its exciting developments, visit their official website at www.innocanpharma.com.